Immupharma PLC EIS and VCT Qualifying Status and Issue of Equity (5354Q)
March 01 2016 - 2:02AM
UK Regulatory
TIDMIMM
RNS Number : 5354Q
Immupharma PLC
01 March 2016
1 MARCH 2016
ImmuPharma PLC
Confirmation of EIS and VCT Qualifying Status and Issue of
Equity
GBP8.4 million total proceeds raised by ImmuPharma within the
recent Placing and Subscription
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the
specialist drug discovery and development company, announces that
it has received advance assurance from HM Revenue and Customs that
it is a qualifying holding for the purposes of the Venture Capital
Trust rules ("VCT Advance Assurance") and a qualifying company for
the purposes of the Enterprise Investment Scheme ("EIS Advance
Assurance", together the "Assurances").
Following receipt of the Assurances, the Company is pleased to
announce the issue and allotment of the 2,856,539 new ordinary
shares of 10 pence each (the "New Ordinary Shares") in respect of
the EIS Shares and VCT Shares within the Placing and Subscription
as described in the announcements on 5 February 2016 and 24
February 2016. This brings the total proceeds raised by the Company
in connection with the Placing and Subscription to GBP8.4
million.
Application will be made to the London Stock Exchange plc for
the admission of the 2,856,539 New Ordinary Shares to trading on
AIM ("Admission"). Admission is expected to take place at 8 a.m. on
4 March 2016 (or such later date as Panmure Gordon and the Company
may agree, being not later than 8 a.m. on 24 March 2016) at which
time the Placing and Subscription will become unconditional.
Dealings in the New Ordinary Shares on AIM will commence at the
same time. The New Ordinary Shares will be issued credited as fully
paid and will be identical to, and rank pari passu in all respects
with, the existing ordinary share capital in the Company, including
the right to all dividends and other distributions declared, made
or paid in respect of the existing ordinary share capital following
the date of Admission.
Following the issue of the New Ordinary Shares referred to
above, ImmuPharma will have 121,781,219 ordinary shares of 10 pence
each (the "Ordinary Shares") in issue. No Ordinary Shares are held
in treasury. Shareholders may use the above figure as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under section 5 of the FCA's Disclosure
and Transparency Rules.
Ends
For further information please see the Company's website,
www.immupharma.org, or contact:
ImmuPharma plc + 44 (0) 20 7152
Tim McCarthy, Chairman 4080
Lisa Baderoon, Head of Investor
Relations + 44 (0) 7721 413496
lisa.baderoon@immupharma.com
Panmure Gordon (Financial Adviser,
Nominated Adviser & Broker)
Fred Walsh, Duncan Monteith,
Corporate Finance
Charles Leigh-Pemberton, Corporate
Broking +44 (0) 20 7886 2500
Notes on Assurances
Shareholders should be mindful that EIS Advance Assurance and
VCT Advance Assurance qualification rules are subject to change and
no guarantees or assurance can be given in this regard.
This information is provided by RNS
The company news service from the London Stock Exchange
END
LISSESFWUFMSELE
(END) Dow Jones Newswires
March 01, 2016 02:02 ET (07:02 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024